Archive for the ‘Gene Therapy Research’ Category

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/nc5lqz/genetic_testing) has announced the addition of the "Genetic Testing Market Outlook to 2017" report to their offering.

A recent report, Genetic Testing Market Outlook to 2017, provides an in-depth analysis of the current and future genetic testing market. A comprehensive introduction of gene-based tests, their working principles and types are covered in around a 140-page report. On account of our analysis of the past and present market trends; drivers; and existing strengths and challenges; forecast for genetic testing has been drawn, according to which, the market is likely to grow at a CAGR of around 9% during 2012-2017.

Our report is an outcome of extensive interaction with industry experts which has led us to portray the updated status of genetic testing in various therapeutic areas, major geographies and significant industry applications. The genetic testing industry has seen several new product launches, active research innovations, strategic activities, launch of new DTC tests, and wider therapeutic applications.

The report effectively illustrates the role of genetic testing in diseases such as Cancer, Cystic Fibrosis, and Alzheimer. It also incorporates the information on disease prevalence, available tests, and genes that cause a particular disease. An extensive research and reliable statistics in terms of market size, developments and future performance for emerging sectors namely, Next-Generation Sequencing, Whole Genome Sequencing, Non Invasive Prenatal Diagnostics, and Personalized Medicine have been covered in the report.

Genetic testing is growing in both developing and developed nations with both industry and research personnel highlighting the significance of molecular biology. The report provides comprehensive analytics of key developments for major markets including the U.S., Europe and Asian countries, and their market overview. Country level analysis depicts the level of penetration for genetic testing, types of tests available, consumer perspectives, regulatory stringency and future growth.

Companies Mentioned

- Abbott Laboratories

- Clarient (GE Healthcare)

- Dako (Agilent Technologies)

Read this article:
Research and Markets: Genetic Testing Market Outlook to 2017

Public release date: 20-May-2013 [ | E-mail | Share ]

Contact: Samuli Ripatti samuli.ripatti@helsinki.fi 358-405-670-826 University of Helsinki

The study comprised over 24,000 Finnish subjects and was led by Professor Samuli Ripatti. The results revealed that a panel of 28 genetic markers improved detection of individuals with high risk for coronary heart disease (CHD) (10-year risk 20%) over traditional risk factors.

Identification of high-risk individuals is an important preventive strategy for CHD, because the current guidelines recommend statin treatment for the high-risk group. "The results indicate that genetic markers could be useful in CHD prevention, when used in addition to traditional risk factor screening", said Professor Veikko Salomaa from National Institute for Health and Welfare.

The study shows that genetic screening of individuals at intermediate risk (10-20%) based on traditional risk factors would reclassify 12% of them into the high-risk group. "Statin treatment of the reclassified individuals could prevent hundreds or even thousands of CHD events in Finland. The results are based on large population cohorts but should nevertheless be tested in a clinical setting. Pilot projects studying the effect of this new genetic information on health behavior are now being carried out", said Professor Samuli Ripatti.

Genetic markers improved prediction more efficiently than family history of the disease. Information on family history has been used to reflect genetic risk and it is commonly used in CHD risk evaluation. The results of the study demonstrate the potential for genetic screening of CHD in combination with traditionally screened risk factors in Finland.

###

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

Follow this link:
Genetic screening could reveal hidden high risk for coronary heart disease

Mendel #39;s Work on Genetics
Brief history of Gregor Mendel #39;s work, plus an example of his "Pea Plant" experiments, with modern interpretation in terms of PP, Pp, and pp, hetero- and hom...

By: Michael Auerbach

More here:
Mendel's Work on Genetics - Video

Charles Lee

FARMINGTON Harvard genetics expert Charles Lee, Ph.D., has been appointed scientific director of The Jackson Laboratory for Genomic Medicine.

Lee is a world renowned scientist best known for his discovery that copy-number variation a state in which cells have an abnormal number of copies of DNA sections, sometimes associated with susceptibility or resistance to disease is widespread and significant in the human genome.

Lee currently directs both the molecular genetics research unit at Brigham and Womens Hospital and the cytogenetics facility for the Harvard Cancer Center in Boston.

For his discoveries and research into the human genome, Lee has received numerous accolades and awards, including the 2008 Ho-Am Prize in Medicine, often referred to as the Korean version of the Nobel Prize, and a Chen Global Investigator award from the International Human Genome Organization. He is also an elected fellow of the American Association for the Advancement of Science.

Lee will be responsible for the scientific direction and coordination of JAX Genomic Medicine in Farmington, Connecticut.

Connecticut Gov. Dannel P. Malloy hailed Lees appointment as another major milestone in a growing biomedical research economy.

Dr. Lee is an excellent addition to Connecticuts scientific community, Malloy said. His work will highlight our leadership in the bioscience sector and our commitment to creating good paying jobs with good benefits. With our investment in JAX and the bioscience industry, we have turned a corner on decades of no job growth.

Continued here:
Harvard genetics expert named scientific director at Jackson Laboratory for Genomic Medicine

LOS ANGELES, May 20, 2013 (GLOBE NEWSWIRE) -- Response Genetics, Inc. (RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, today announced that abstracts will be presented at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL May 31 to June 4, 2013. The abstracts demonstrate the clinical utility of Response Genetics' proprietary ResponseDX(R) ERCC1 gene expression test in colon, pancreatic, and lung cancer and the emerging finding that gene mutation and expression profiles in colorectal cancer are associated with tumor location within the colon and rectum.

Poster Discussion Session Gene expression profiles and tumor locations in colorectal cancer (left vs. right vs. rectum) Date/Time Poster Display: June 4, 2013, 8:00AM -- 12:00PM, Location: S405 Date/Time Poster Discussion: June 4, 2013, 11:30AM -- 12:30PM, Location: S406

Poster Session Correlation of ERCC1 mRNA expression with KRAS mutation status in colorectal, pancreatic, and lung adenocarcinoma Date/Time: June 3, 2013, 1:15PM -- 5:00PM, Location: S Hall A2

About Response Genetics, Inc.

Response Genetics, Inc. (the "Company") is a CLIA-certified clinical laboratory focused on the development and sale of molecular diagnostic testing services for cancer. The Company's technologies enable extraction and analysis of genetic information derived from tumor cells stored as formalin-fixed and paraffin-embedded specimens. The Company's principal customers include oncologists and pathologists. In addition to diagnostic testing services, the Company generates revenue from the sale of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry. The Company's headquarters is located in Los Angeles, California. For more information, please visit http://www.responsegenetics.com.

Forward-Looking Statement Notice

Except for the historical information contained herein, this press release and the statements of representatives of the Company related thereto contain or may contain, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995.

Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions, such as the ability of the Company, to provide clinical testing services to the medical community, to continue to strengthen and expand its sales force, to continue to build its digital pathology initiative, to attract and retain qualified management, to continue to strengthen marketing capabilities, to expand the suite of ResponseDX(R) products, to continue to provide clinical trial support to pharmaceutical clients, to enter into new collaborations with pharmaceutical clients, to enter into areas of companion diagnostics, to continue to execute on its business strategy and operations, to continue to analyze cancer samples and the potential for using the results of this research to develop diagnostic tests for cancer, the usefulness of genetic information to tailor treatment to patients, and other statements identified by words such as "project," "may," "could," "would," "should," "believe," "expect," "anticipate," "estimate," "intend," "plan" or similar expressions.

These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities Exchange Commission. Actual results, including, without limitation, actual sales results, if any, or the application of funds, may differ from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by law.

See the article here:
Response Genetics, Inc. Announces Presentations at the American Society of Clinical Oncology 2013 Annual Meeting

SEATTLE, WA--(Marketwired - May 20, 2013) - Atossa Genetics, Inc. (NASDAQ: ATOS), the Breast Health Company, today announced that Dr. Steven Quay, chairman, CEO and president, will be presenting at the Sidoti Semi-Annual Microcap Conference on Friday, June 7, 2013, at 2:00 p.m. Eastern Time, at the Grand Hyatt Hotel in New York City. In addition to presenting the company story, management will be available for one-on-one meetings with institutional investors.

For more information about the conference or to schedule a one-on-one meeting with Atossa's management, please contact your Sidoti representative or visit http://www.sidoti.com.

About Atossa Genetics, Inc.

Atossa Genetics, Inc. (NASDAQ: ATOS) (www.atossagenetics.com), The Breast Health Company, is based in Seattle, WA, and is focused on preventing breast cancer through the commercialization of patented diagnostic medical devices and patented laboratory developed tests that can detect precursors to breast cancer up to eight years before mammography, and through research and development that will permit it to commercialize treatments for pre-cancerous lesions.

The National Reference Laboratory for Breast Health (NRLBH; http://www.nrlbh.com), a wholly owned subsidiary of Atossa Genetics, Inc., is a CLIA-certified high-complexity molecular diagnostic laboratory located in Seattle, WA. The NRLBH provides the patented ForeCYTE Breast Health Test, a risk assessment test for women 18 to 73 years of age akin to the Pap Smear, and the ArgusCYTE Breast Health Test, a blood test for recurrence in breast cancer survivors that provides a "liquid biopsy" for circulating breast cancer cells and a tailored treatment plan for patients and their caregivers.

Link:
Atossa Genetics to Present at the Sidoti Semi-Annual Microcap Conference

WALTHAM, Mass.--(BUSINESS WIRE)--

Interleukin Genetics, Inc. (ILIU) announced today that it will host a conference call and Webcast on Thursday, May 23, 2013 at 4:30 p.m. (EST) to provide a corporate update and discuss the Companys first quarter results.

To access the live call, dial 877-324-1976 (domestic) or 631-291-4550 (international). The live Webcast and replay access of the teleconference will be available on the Investors section of Interleukin Genetics, Inc.s Website at http://www.ilgenetics.com.

About Interleukin Genetics

Interleukin Genetics, Inc. (ILIU) develops and markets a line of genetic tests under the Inherent Health and PST brands.The products empower individuals to prevent certain chronic conditions and manage their existing health and wellness through genetic-based insights with actionable guidance. Interleukin Genetics leverages its research, intellectual property and genetic panel development expertise in metabolism and inflammation to facilitate the emerging personalized healthcare market. The Company markets its tests through partnerships with health and wellness companies, healthcare professionals and other distribution channels. Interleukin Genetics flagship products include its proprietary PST genetic risk panel for periodontal disease and tooth loss susceptibility sold through dentists, and the Inherent Health Weight Management Genetic Test that identifies the most effective diet and exercise program for an individual based on genetics. Interleukin Genetics is headquartered in Waltham, Mass. and operates an on-site, state-of-the-art DNA testing laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). For more information, please visit http://www.ilgenetics.com.

.

Read the original post:
Interleukin Genetics, Inc. Announces Conference Call to Discuss First Quarter 2013 Results

WALTHAM, Mass.--(BUSINESS WIRE)--

Interleukin Genetics, Inc. (ILIU) announced today that it has raised $12.0 million in gross proceeds through a private placement of its securities to accredited investors. Interleukin sold an aggregate of 43,715,847 shares of its common stock at a price of $0.2745 per share and issued warrants to purchase an aggregate of 32,786,885 shares of common stock at an exercise price of $0.2745 per share to the investors.

Subject to future approval by Interleukins shareholders of an increase in the number of authorized shares of common stock, each investor has the right, prior to June 30, 2014, to purchase its pro rata share of up to an aggregate of $5,000,000 of additional shares of common stock and warrants on the same terms and conditions as those set forth above.

Immediately prior to the closing of this transaction Pyxis Innovations Inc., the sole holder of Interleukins Series A-1 Preferred Stock, converted all outstanding shares of Series A-1 Preferred Stock into 28,160,200 shares of common stock and converted all of Interleukins outstanding convertible debt ($14,316,255) into 2,521,222 shares of common stock. Delta Dental Plan of Michigan, Inc., the sole holder of the Companys outstanding Series B Preferred Stock, also converted all outstanding shares of Series B Preferred Stock into 10,928,961 shares of common stock. Accordingly, following the transaction, the Company has no outstanding preferred stock or convertible debt.

BTIG, LLC acted as the exclusive placement agent for the transaction.

The securities offered in the private placement have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or applicable state securities laws. Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.

This release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state.

Further details of the transaction, including information with respect to the restructuring of Interleukins Board of Directors, will be described in a Current Report on Form 8-K to be filed with the SEC by the Company.

About Interleukin Genetics, Inc.

Interleukin Genetics, Inc. (ILIU) develops and markets a line of genetic tests under the Inherent Health and PST brands.The products empower individuals to prevent certain chronic conditions and manage their existing health and wellness through genetic-based insights with actionable guidance. Interleukin Genetics leverages its research, intellectual property and genetic panel development expertise in metabolism and inflammation to facilitate the emerging personalized healthcare market. The Company markets its tests through partnerships with health and wellness companies, healthcare professionals and other distribution channels. Interleukin Genetics flagship products include its proprietary PST genetic risk panel for periodontal disease and tooth loss susceptibility sold through dentists and the Inherent Health Weight Management Genetic Test that identifies the most effective diet and exercise program for an individual based on genetics. Interleukin Genetics is headquartered in Waltham, Mass. and operates an on-site, state-of-the-art DNA testing laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA).

See the original post here:
Interleukin Genetics Announces $12 Million Private Placement

Treatment of a patient with Parkinson #39;s Disease using stem cell therapy
Here we demonstrate how a patient who suffers from Parkinson #39;s Disease has benefited from stem cell therapy with us in Panama.

By: SCRMPanama

See the original post:
Treatment of a patient with Parkinson's Disease using stem cell therapy - Video

Businessman had an increased risk of cancer through the BRCA2 gene He entered a trial at the Institute of Cancer Research as it ran in his family The BRCA1 and BRCA2 genes are linked to an aggressive form of cancer Angelina Jolie had a double mastectomy after testing positive for BRCA1

By Amanda Perthen

PUBLISHED: 19:19 EST, 18 May 2013 | UPDATED: 04:29 EST, 19 May 2013

A British father has made medical history by having his healthy prostate removed after discovering that he carries a defective gene that boosts his risk of cancer, it was reported last night.

The businessmans increased risk of cancer through the BRCA2 gene is believed to have come to light when he took part in a trial at the Institute of Cancer Research (ICR) in London.

He entered the trial because he has relatives who have suffered from breast or prostate cancer in the past.

Scientists believe that others who know they are carriers will choose to go down the same route (stock image)

The BRCA1 and BRCA2 genes are known to be linked to an aggressive form of breast cancer.

Last week Hollywood actress Angelina Jolie revealed she had had surgery to remove both her breasts to reduce the risk of getting breast cancer after testing positive for the rogue BRCA1 gene.

Visit link:
British father, 53, has prostate removed after being told he carried defective gene that boosts his chance of cancer

Angelina Jolie has revealed she underwent a double masectomy when tests revealed genes associated with breast cancer

A 53-year-old British father has become the first man to have his prostate removed because tests revealed he was carrying a "faulty" cancer gene.

A clinical trial at London's Institute of Cancer Research revealed that he carried the BRCA2 gene, which research shows is associated with a high risk of developing prostate cancer.

Several of the man's family had suffered from breast or prostate cancer, which is why he took part in the study.

The closely associated BRCA1 gene has been known for some time to have links with breast cancer, and last week actress Angelina Jolie revealed that she had undergone a double mastectomy when tests revealed that she carried the gene.

Follow us

After receiving the news the man asked doctors to remove his prostate, which tests had shown to be healthy.

Surgeons were initially reluctant, since the potential side effects of the operation include infertility, incontinence and sexual dysfunction.

MRI scans and a prostate-specific antigen, or PSA tests, did not show the presence of malignant cells, but microscopic examination revealed cell changes associated with cancer, prompting the surgeons to act.

Surgeon Roger Kirby told the Sunday Times: "The relatively low level of cancerous cells we found in this man's prostate before the operation would these days not normally prompt immediate surgery to remove the gland, but given what we now know about the nature of BRCA2, it was definitely the right thing for this patient."

Here is the original post:
UK Man has Prostate Removed After Tests Reveal 'Jolie' Gene Flaw

Fill a pool with giant amounts of chocolate pudding.

Pay for the genetic engineering of a real-life unicorn.

Do something boring like pay off your debt, send your kids to college or start a charity that could, like, solve world hunger or something.

All of these things can (might?) be done if you win the now-all-time-high Powerball jackpot of $600 million, according to the Powerball website.

The next drawing is Saturday and the world waits with bated breath to see who will be the next mega-rich and mega-lucky winner.

Well, not that lucky the Powerball website says the jackpot is only worth $376.9 million in cash only.

The last drawing on Wednesday paid out almost $47,00,000 in non-jackpot prizes around the country and nearly 2.7 million people could count themselves as winners. However, no one claimed the biggest prize.

Michigan already has seen its share of luck so far in the latest lottery craze. A $1 million ticket was sold in tiny Blanchard, sending the locals into a lottery-fueled delirium, according to MLive.

Get creative and tell us what you'd buy with the money if you got the lucky numbers on Saturday in the comments.

Good luck, lottery-playing Ann Arborites. Youll need it.

Here is the original post:
What would you buy? Powerball jackpot reaches $600 million

The reality is sobering. Ten to 15 years ago we thought that we would be using genetic tests to predict all sorts of diseases, said Prof Tim Spector, a genetic epidemiologist at Kings College London. It turns out to have been wishful thinking.

We used to think there might be five to 10 genes involved in a disease, but we now know there may be thousands that only contribute a tiny amount and interact with each other.

It was hoped that the 1.8 billion human genome project to decipher our DNA would herald a new age in medicine when it was completed 13 years ago. Instead, it revealed that our genetic make up is far more complicated than we had expected.

None the less, scientists have now developed tests for about 2,500 diseases, but almost all are for rare conditions and only a fifth are treatable. Examples include Huntingdons Disease and Cystic Fibrosis.

However, scientists who worked on the human genome project are now striving to unravel the web of genes that play a role in more widespread conditions including obesity, diabetes and autism.

They are analysing the genomes of more than 10,000 people from around the UK who suffer from a range of diseases.Their results are already identifying genes that have weak effects in serious and common conditions.

These may not be useful as a test in themselves, said Dr Jeff Barrett, group leader on the UK10K project at the Wellcome Trust Sanger Institute. But they will help us understand more about these diseases. This can give us clues about how to develop treatments and to develop new ways of screening.

Also on the horizon are new tests for, diabetes, early-onset Alzheimers disease and colon cancer, which may help doctors provide treatments to slow them or prevent them from occurring.

Tests for obesity genes can also present people with the option of changing their behaviour and diet to reduce their chances of becoming obese.

Simultaneously, the development of genetic tests is also resulting in a growing ethical and moral debate about how they should be used. By providing seemingly healthy individuals with a warning that they may suffer from an illness later in their life, doctors are also offering them the chance to prevent it.

More here:
Where is genetic testing taking us?

If you underwent a genetic test for a heart condition, but the test also revealed that you have a high risk of colon cancer, would you want to know?

A respected scientific society says your doctor should tell you, but the group is receiving criticism for its recommendation that "incidental findings" of genetic tests be shared with patients.

Incidental findings are unexpected results, unrelated to the reason for testing. What to do with these findings has been a controversial issue for adults undergoing genetic testing, as well as children.

In March, the American College of Medical Genetics and Genomics (ACMG) released guidelines saying that when patients receive genetic testing for any medical reason, they should be screened for mutations in an additional 57 genes, including mutations that strongly increase the risk of breast, ovarian and colon cancer.

The ACMG argues that doctors have an obligation to look for and report these mutations because there are ways that people can act to reduce their of developing a medical disorder.

However, some researchers and bioethicists say the new recommendations go too far, and take away patients' rights to refuse medical information they do not wish to know.

Informed consent

A crucial part of genetic testing ethics is ensuring that patients understand what a test might find, and what those findings could mean for future treatment.

Under the new recommendations, a patient who consents to any genetic test is consenting to be screened for mutations in an additional 57 genes. Some bioethicists take issue with this approach, because patients may not wish to know their results for all of these genes.

A positive result for any one of these mutations may increase patients' anxiety, or cause them to live their life differently, said Susan Wolf, a professor of law, medicine and public policy at the University of Minnesota.

Read the rest here:
Genetic Testing Guidelines Under Fire

Frankie riding Sweet Genetics for the first time!
This video was uploaded from an Android phone.

By: mistydreamsfarm

See the article here:
Frankie riding Sweet Genetics for the first time! - Video

Quantitative Genetics

By: MepoBulldogFootball

See original here:
Quantitative Genetics - Video

GOODIE MOB Live On BET (Cell Therapy/They Dont Dance No Mo)
GOODIE MOB LIVE ON BET PERFORMING(Cell Therapy/They Dont Dance No Mo)

By: JROOKZ ENT

See the rest here:
GOODIE MOB Live On BET (Cell Therapy/They Dont Dance No Mo) - Video

GCSE Bio Genetic Engineering of Insulin
1 minute quick draw revision on genetic engineering of insulin.

By: DrRoseatcrispins

See the rest here:
GCSE Bio Genetic Engineering of Insulin - Video

Monsanto Genetic Engineering Scam
March Against Monsanto https://www.facebook.com/MarchAgainstMonstanto Unlicensed footage is used in accordance with Section 107 of US Copyright Law.

By: DARKSIDEHELL1

Read the original here:
Monsanto Genetic Engineering Scam - Video

Modded Minecraft S4E16: Sniffling, sneezing, storage, and genetic engineering
Wherein I park my ass in front of the computer long enough to record something for my peeps, we address the problem of our quickly-filling storage by buildin...

By: nightdagger

Read the rest here:
Modded Minecraft S4E16: Sniffling, sneezing, storage, and genetic engineering - Video

NEW YORK, May 17, 2013 /PRNewswire/ --Sudler & Hennessey, one of the leading global healthcare communication agencies, announces an agreement between Sudler's eHealth Group and NextGxDx, an online genetic testing marketplace for healthcare providers and hospitals.

Emerging trends in healthcare focus on cost, quality, and access to care and information. As personalized medicine continues to expand, and as new genetic tests are introduced daily, integration of these tests into clinical practice is a growing challenge for healthcare providers. The innovative NextGxDx solution consolidates and curates data on genetic tests to help users compare and order tests in a simple way that reduces paperwork and streamlines the ordering process leading to more time with their patient.

This is especially critical now as the NIH announced that Genetests.org, one of the most commonly used gene test databases, is being discontinued on June 4, 2013.

"Working with the Sudler eHealth Group is an excellent opportunity to drive awareness, and Sudler's knowledge of physician engagement is another innovative step for us to take in connecting with healthcare professionals. Collectively, NextGxDx and Sudler eHealth will drive change in the way genetic tests are researched and ordered," said Mark Harris, PhD, CEO of NextGxDx.

According to Cassandra Sinclair, Managing Director eHealth Group, "We're very excited to be working with NextGxDx as they build a new marketplace for genetic testing that will create transparency in the industry. Our strategic expertise, integrated insights, and creative capabilities, along with our decades of healthcare experience, will significantly help NextGxDx meet the next milestone".

The Sudler eHealth Group partners with health information technology (HIT) companies to effectively tap into the healthcare market through strategic communications, education, and training of healthcare professionals. Using its strategic, integrated insights and capabilities, they have moved markets for their pharmaceutical clients and will use this foundation and experience to help HIT companies drive market change at the point of care.

If you would like more information about how Sudler's eHealth Group can help find solutions, visit http://www.sudlerehealth.com or contact any of our eHealth leaders:

Cassandra Sinclair, cassandra.sinclair@sudlerehealth.com

R. Shane Kennedy, shane.kennedy@sudlereheatlh.com

About NextGxDxNextGxDx provides an online genetic testing marketplace that offers healthcare professionals and hospitals the ability to access up-to-date listings of all genetic tests from CLIA-certified laboratories, view pertinent information about each test, order tests online, and manage results electronically within the HIPAA-compliant portal.By providing clinicians with a one-stop-shop to search, compare, and order genetic tests, NextGxDx reduces the time and costs associated with the ordering of genetic tests.For more information, visit http://www.NextGxDx.com.

Go here to see the original:
SUDLER's eHealth Group Signs Agreement With NextGxDx

Genetics Semester Test Overview

By: MepoBulldogFootball

View post:
Genetics Semester Test Overview - Video

Response to Elliots Ab Genetics Video
My Feedback on ab genetics and how important they are.

By: Albert Dolan

Read more:
Response to Elliots Ab Genetics Video - Video

Genetics lecture

By: Mike Naughton

Excerpt from:
Genetics lecture - Video

Genetics 005
law of independent assortment,gene,chromosome grade x.

By: Sandeep Changlani

Read the original post:
Genetics 005 - Video